Expert Analysis

Acute Leukemias

Source: CCO Independent Conference Coverage of the American Society of Hematology 2007 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Acute Leukemias

Program Director: Roy A. Beveridge, MD

Faculty:

Dan Douer, MD
Stephen J. Forman, MD
Hagop M. Kantarjian, MD

Moderator: Mark Kirschbaum, MD

CME CREDIT INFORMATION

Release Date: 02/26/08

Expiration Date: 02/25/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.2 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss new data about the selection of anthracycline antibiotics in induction treatment of acute myeloid leukemia
Explain how recent data on allogeneic stem cell transplantation in patients with acute myeloid leukemia may influence clinical practice
Identify the possible benefits and risks of using pediatric chemotherapy regimens in adult patients with acute lymphoblastic leukemia
Summarize the role of imatinib in regimens used to treat acute lymphoblastic leukemia
Discuss the significance of CD20 expression in prognosis and treatment of acute lymphoblastic leukemia

Topics covered include:

Treatment Trials in Acute Myeloid Leukemia: Anthracyclines in Induction, Interleukin-2 in Maintenance
Allogeneic Stem Cell Transplantation in High-Risk Acute Myeloid Leukemia: Unrelated Donors Offer Good Outcomes
Treatment and Long-Term Survival in Acute Myeloid Leukemia
Pediatric Chemotherapy Regimens in Adults With Newly Diagnosed Acute Lymphoblastic Leukemia
HyperCVAD and Imatinib in Acute Lymphoblastic Leukemia
CD20 is Prognostic in Adult B-Cell Acute Lymphoblastic Leukemia
Conclusion and Summary

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.